|
| 36347760 | Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235]. | Eur J Cancer | 2022 |
| 36347760 | Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235]. | Eur J Cancer | 2022 |
| 35689897 | Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. | Eur J Cancer | 2022 |
| 35689897 | Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. | Eur J Cancer | 2022 |
| 34652968 | Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. | J Clin Oncol | 2021 |
| 33720485 | Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study. | Pediatr Blood Cancer | 2021 |
| 34652968 | Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. | J Clin Oncol | 2021 |
| 33720485 | Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study. | Pediatr Blood Cancer | 2021 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32167861 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. | J Clin Oncol | 2020 |
| 32167861 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. | J Clin Oncol | 2020 |
| 30685685 | Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. | Eur J Cancer | 2019 |
| 31573951 | Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. | JMIR Res Protoc | 2019 |
| 32154021 | Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. | Cardiooncology | 2019 |
| 31553693 | High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. | J Clin Oncol | 2019 |
| 30266815 | Genome-Informed Targeted Therapy for Osteosarcoma. | Cancer Discov | 2019 |
| 31094225 | Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. | Future Oncol | 2019 |
| 30685685 | Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. | Eur J Cancer | 2019 |
| 32154021 | Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. | Cardiooncology | 2019 |
| 31553693 | High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. | J Clin Oncol | 2019 |
| 31573951 | Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. | JMIR Res Protoc | 2019 |
| 31094225 | Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. | Future Oncol | 2019 |
| 30266815 | Genome-Informed Targeted Therapy for Osteosarcoma. | Cancer Discov | 2019 |
| 28721605 | How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Â h: the Stanford Approach. | Mol Imaging Biol | 2018 |
| 28721605 | How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Â h: the Stanford Approach. | Mol Imaging Biol | 2018 |
| 28837220 | Reply to Second malignancies in Ewing sarcoma survivors. | Cancer | 2017 |
| 28837220 | Reply to Second malignancies in Ewing sarcoma survivors. | Cancer | 2017 |
| 28222219 | Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. | Cancer | 2017 |
| 28222219 | Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. | Cancer | 2017 |
| 26982677 | Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. | Radiology | 2016 |
| 29672009 | Assessment of Chemotherapy Response in Ewing Sarcoma: Response | Radiology | 2016 |
| 27297500 | Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2016 |
| 27128693 | Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. | Pediatr Blood Cancer | 2016 |
| 27216741 | Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. | Ann Surg Oncol | 2016 |
| 26776342 | Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. | J Surg Oncol | 2016 |
| 26982677 | Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. | Radiology | 2016 |
| 26257296 | Identification of Discrete Prognostic Groups in Ewing Sarcoma. | Pediatr Blood Cancer | 2016 |
| 26579879 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. | Pediatr Blood Cancer | 2016 |
| 27569442 | Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. | Lancet Oncol | 2016 |
| 29672009 | Assessment of Chemotherapy Response in Ewing Sarcoma: Response | Radiology | 2016 |
| 26579879 | Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. | Pediatr Blood Cancer | 2016 |
| 26257296 | Identification of Discrete Prognostic Groups in Ewing Sarcoma. | Pediatr Blood Cancer | 2016 |
| 27297500 | Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2016 |
| 27216741 | Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. | Ann Surg Oncol | 2016 |
| 27128693 | Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. | Pediatr Blood Cancer | 2016 |
| 27569442 | Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. | Lancet Oncol | 2016 |
| 26776342 | Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. | J Surg Oncol | 2016 |
| 25251206 | Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. | Cancer | 2015 |
| 25464386 | Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. | Pediatr Blood Cancer | 2015 |